Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Dianthus Therapeutics Inc shares valued at $903,600 were sold by Savitz Ryan on Dec 04 ’25. At $45.18 per share, Savitz Ryan sold 20,000 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
Also, RYAN SAVITZ purchased 20,000 shares, netting a total of over 879,400 in proceeds.
Before that, Randhawa Simrat had sold 109,031 shares from its account. In a trade valued at $4,158,442, the EVP, Head of R&D traded Dianthus Therapeutics Inc shares for $38.14 each. Upon closing the transaction, the insider’s holdings decreased to 109,031 shares, worth approximately $0.17 million.
As published in their initiating research note from Truist on October 14, 2025, Dianthus Therapeutics Inc [DNTH] has been a Buy and the price target has been revised to $56. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in early July. As of December 20, 2024, TD Cowen has initiated its “Buy” rating for DNTH. Earlier on October 03, 2024, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for DNTH stock.
Analyzing DNTH Stock Performance
On last trading session, Dianthus Therapeutics Inc [NASDAQ: DNTH] rose 0.07% to $41.43. The stock’s lowest price that day was $40.77, but it reached a high of $42.38 in the same session. During the last five days, there has been a drop of approximately -4.93%. Over the course of the year, Dianthus Therapeutics Inc shares have jumped approximately 74.00%. Shares of the company reached a 52-week high of $45.46 on 12/04/25 and a 52-week low of $13.36 on 04/09/25.
Support And Resistance Levels for Dianthus Therapeutics Inc (DNTH)
According to the 24-hour chart, there is a support level at 40.67, which, if violated, would cause prices to drop to 39.92. In the upper region, resistance lies at 42.28. The next price resistance is at 43.14. RSI (Relative Strength Index) is 50.99 on the 14-day chart, showing neutral technical sentiment.
Is Dianthus Therapeutics Inc subject to short interest?
Stocks of Dianthus Therapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by -0.31 million shares to 3.71 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 4.03 million shares. A decline of -8.44% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.27 of the overall float, the days-to-cover ratio (short ratio) decline to 5.27.
Which companies own the most shares of Dianthus Therapeutics Inc (DNTH)?
In terms of Dianthus Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 59 in the next 12 months, up nearly 42.51% from the previous closing price of $41.4. Analysts anticipate Dianthus Therapeutics Inc stock to reach 100 by 2025, with the lowest price target being 51. In spite of this, 6 analysts ranked Dianthus Therapeutics Inc stock as Buy at the end of 2025. On July 26, 2024, Robert W. Baird assigned a price target of “an Outperform” to the stock and initiated coverage with a $58.
